Rubin Jeffrey D, Ayasoufi Katayoun, McGlinch Erin B, Hansen Michael J, Harris Peter C, Torres Vicente E, Barry Michael A
Virology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN, USA.
Department of Immunology, Mayo Clinic, Rochester, MN, USA.
bioRxiv. 2025 Jun 2:2025.05.28.656514. doi: 10.1101/2025.05.28.656514.
A variety of genetic diseases of the kidney tubule are amenable to correction via gene therapy. However, gene delivery to renal tubule epithelial cells mediated by viral vectors via the blood is inefficient due to the permselectivity of the glomerular barrier. We hypothesized that effacement of podocyte foot processes would disrupt typical glomerular limitations on filtration and make renal tubule epithelial cells susceptible to transduction from viral vectors delivered intravenously. We determined that adeno-associated virus serotype 8 (AAV8) transduced significantly more epithelial cells in the kidney under the conditions of LPS-induced proteinuria. Use of AAV1 in tandem with LPS-induced proteinuria yielded an ideal two-pronged effect of both partially detargeting the liver and transducing the kidney with a higher bioluminescent signal than AAV8 did, and at half of the dose. Using adenovirus serotype 5 (Ad5) in conjunction with LPS-induced proteinuria showed that kidney transduction was enhanced, but only in glomerular cells. These studies mechanistically test the efficacy of different viral vectors and demonstrate their capacity to transduce kidney epithelial cells. This is a fundamental step in designing future treatments for kidney gene therapy.
多种肾小管遗传性疾病可通过基因治疗得到纠正。然而,由于肾小球屏障的选择通透性,通过血液由病毒载体介导的基因传递至肾小管上皮细胞的效率很低。我们推测,足细胞足突的消失会破坏典型的肾小球滤过限制,并使肾小管上皮细胞易于被静脉注射的病毒载体转导。我们确定,在脂多糖诱导蛋白尿的条件下,8型腺相关病毒(AAV8)能显著转导更多的肾上皮细胞。将AAV1与脂多糖诱导的蛋白尿联合使用,产生了一种理想的双管齐下的效果,既能部分减少肝脏靶向性,又能以比AAV8更高的生物发光信号转导肾脏,且剂量仅为AAV8的一半。将5型腺病毒(Ad5)与脂多糖诱导的蛋白尿联合使用表明,肾脏转导增强,但仅在肾小球细胞中。这些研究从机制上测试了不同病毒载体的疗效,并证明了它们转导肾上皮细胞的能力。这是设计未来肾脏基因治疗方案的一个基本步骤。